The establishment of reliable in vitro intestinal inflammation models and IBD animal models provide valuable tools to expedite the development of therapies for IBD. As a leading preclinical contract research provider for IBD, Ace Therapeutics offers a wide range of customized in vivo and in vitro models of IBD to support drug discovery and preclinical development programs.
Ace Therapeutics' experimental models mimic aspects of IBD in humans and can be used to generate target validation and mechanism of action data to confirm the efficacy of novel therapies. We can work with you to customize your study design to effectively achieve your project goals.
These IBD animal models allow us help clients evaluate novel drugs and therapies and provide valuable insight into disease mechanisms and potential treatment options.
DSS-induced acute colitis mouse model
DSS-induced chronic colitis mouse model
TNBS/DNBS-induced mouse colitis model
Acetic acid‐induced colitis in mice
CD4+CD45RBhigh-induced colitis in mice
IL-10 Knockout model of chronic colitis
Naïve T cell transfer induced colitis in mice
C. Rodentium-induced colitis in mice
DSS-induced acute colitis rat model
DSS-induced chronic colitis rat model
TNBS/DNBS-induced rat colitis model
Chemotherapy-induced diarrhea in rats
Acetic acid induced ulcerative colitis in dogs
Spontaneous IBD model in rhesus monkeys DSS-induced chronic IBD model
Ace Therapeutics offers cutting-edge translational models for studying the prevention and intervention of IBD. We employ advanced techniques to evaluate the therapeutic effects of drugs on IBD.
Ace Therapeutics provides reliable cell-based in vitro intestinal inflammation models to support preclinical drug discovery and development programs.
These models allow us to help clients analyze several readouts, including: